Introduction {#s1}
============

The regulation of neurotransmitter level at the site of release is essential for proper neuronal function and requires constant replenishment, capture and removal of excess or aged components in synapses. To address the fundamental topic of synaptic neuropeptide homeostasis we focused on the well-studied neuropeptide, oxytocin (OXT). Oxytocin is a classical evolutionarily conserved neuropeptide, which is involved in the maintenance of various homeostatic functions and whose major axonal release site is the posterior pituitary, also known as the neurohypophysis ([@bib66]; [@bib90]). Thus, hypothalamic neurosecretory cells produce the neuropeptides vasopressin and oxytocin that are packed into large dense core vesicles (LDCV) and are transported along the axons that terminate in the neurohypophysis. Upon physiological demand, the neuropeptide is released into the blood stream to influence the function of target cells throughout the body ([@bib16]; [@bib45]). In contrast to small neurotransmitters synaptic release, which mainly occurs in highly specialized membrane structures called active zones, neuropeptides, such as OXT, are released from LDCVs from any part of the neuron, including dendrites and *en passant* axonal synapses ([@bib19]; [@bib48]; [@bib49]; [@bib62]). Accordingly, axonal termini of hypothalamic magnocellular OXT neurons converge into the neurohypophysis, where they form numerous *en passant* synapses in a form of highly dense axonal varicosities, also known as axonal swellings or Herring bodies ([@bib86]). These structures have been identified as *bona fide* synapses that store OXT-containing LDCV and release them upon physiological demand ([@bib59]; [@bib92]).

The mechanisms that regulate the synaptic OXT vesicles content are unknown. F-actin, one of the major cytoskeleton elements in synapses play a key role in synapse formation ([@bib18]; [@bib30]). Several recent studies reported that F-actin regulates multiple aspects of vesicular homeostasis such as presynaptic vesicular capture, clustering, docking, release, recycling and inter-synaptic exchange ([@bib18]; [@bib30]; [@bib34]; [@bib55]; [@bib57]; [@bib79]; [@bib80]; [@bib88]). Actin is also required for recruitment of multiple synaptic proteins and receptors that are essential for synaptic function ([@bib75]). In rat neurohypophyseal synapses, EM studies have shown that actin filaments are arranged both in the synaptic cytoplasm associated with the vesicles and along the plasma membrane ([@bib1]). Furthermore, perturbation of isolated neurohypophyseal tissue using actin disrupting agents leads to release of OXT, suggesting that cortical actin is required to prevent release of synaptic OXT ([@bib84]).

Here we used a combination of transgenic OXT-specific zebrafish reporters allowing monitoring and quantification of synaptic OXT levels. We investigated the role of actin in synaptic OXT content. We show that Slit3-Robo2-Cdc42 signaling, which was previously associated with modulation of actin polymerization in the growth cones of guided axons, regulates synaptic actin dynamics and OXT neuropeptide content in neurohypophyseal termini.

Results {#s2}
=======

Quantitative analysis of synaptic OXT neuropeptide levels in vivo {#s2-1}
-----------------------------------------------------------------

The optically transparent zebrafish larva has a few dozens of OXT neurons, which enables analysing the function of each neuron down to the single-synapse resolution in the context of a living vertebrate animal ([@bib9]; [@bib91]; [@bib35]). Because zebrafish neurohypophyseal synapses were never characterized, we firstly performed transmission electron microscopy (TEM) to visualize those synapses in zebrafish larva. To localize the neurohypophysis, we used a transgenic reporter, Tg(*oxt*:EGFP), in which neurohypophyseal OXT synaptic varicosities are filled with cytoplasmic EGFP ([Figure 1A](#fig1){ref-type="fig"}). We observed that neurohypohyseal synapses were enriched with multiple large dense core vesicles (LDCV) ([Figure 1B & C](#fig1){ref-type="fig"}). We also observed an occurrence of LDVCs content exocytosis, typical of previously reported synaptic neurosecretion in the neurohypophysis ([@bib13]; [@bib15]; [@bib27]; [@bib28]; [@bib37]; [@bib76]). Neurohypophyseal synapses were located next to the basement membrane of the endothelial cells ([Figure 1B,C](#fig1){ref-type="fig"}). In particular, we observed exocytotic pits, in which the membranes of LDCVs were fused with the plasma membrane, next to the perivascular space ([Figure 1B'](#fig1){ref-type="fig"}, arrow). This was in contrast to axons which contained null or low number of LDCVs which were relatively smaller ([Figure 1B and C](#fig1){ref-type="fig"} yellow dashed lines). Moreover, we detected electron-dense plasma membrane invaginations ([Figure 1C'](#fig1){ref-type="fig"} red arrowhead) and recycled vesicles in the cytoplasm ([Figure 1C'](#fig1){ref-type="fig"}, white arrowhead) indicating a membrane retrieval process by endocytosis. Coupling of synaptic exocytosis and endocytosis is typical for neuronal synapses and considered as a general mechanism for conservation of the cell surface upon neurosecretion ([@bib24]; [@bib26]; [@bib28]; [@bib46]; [@bib74]; [@bib95]).

![Identification and quantification of synaptic OXT content in neurohypophyseal axonal termini.\
(**A--C**) Scheme describing the neurohypophyseal vasculature and synapses in 5 days post-fertilization (dpf) transgenic reporter Tg(*oxt*:EGFP). The dense neurohypophyseal synapses (NS) were used as an anatomical landmark to localize the larval neurohypophysis prior to tissue preparation for Transmission Electron Microscopy (TEM) imaging (**A**). TEM image showing cross-section of axons (yellow dashed line) and neurohypophyseal synapses (red dashed line) (**B,C**). Large dense core vesicles with electron-dense neuropeptides are visible in NS (white arrows). ​Membranal fusion resembling exocytotic pit (black arrow), membranal invagination resembling endocytic pit (red arrow head) and empty vesicle resembling recycled vesicle (white arrow head) are visible in NS (**B',C'**). Ax: axon, BM: basement membrane, EC: endothelial cell and NS: neurohypophyseal synapse. Scale: 500 nM (**B,C**) and 100 nm (**B', C'**). (**D,E**) Oxytocin neuron-specific labeling of synapses using EGFP-fused synaptic vesicle marker synaptophysin-B (**D**). Whole-mount confocal microscope imaging of hypophysis of 5 days post-fertilization (dpf) transgenic Tg(*oxt*:Gal4;UAS:SYP-EGFP) zebrafish following immunostaining with anti-EGFP and a specific antibody against endogenous OXT protein (**E**). Mean weighted colocalization coefficients for OXT fluorescence with respect to GFP fluorescence = 0.87; n = 5 larvae (See Materials and methods for detailed description). Scale: 5 μM. (**F**) Scheme describing the pipeline for detection of neurohypophyseal synapses. Whole-mount confocal microscope imaging of hypophysis of 5 days post-fertilization (dpf) transgenic reporter Tg(*oxt*:EGFP) zebrafish following immunostaining with anti-EGFP and a specific antibody against endogenous OXT protein. Analysis of GFP-positive neurohypophyseal synapses (NS) and OXT puncta were performed by using the 'object identifier' function in Volocity software on individual channels. Scale: 5 μM.\
10.7554/eLife.45650.003Figure 1---source data 1.Experimental data for [Figure 1](#fig1){ref-type="fig"}: colocalization analysis of synaptic OXT and EGFP fluorescence.The excel sheet includes values for weighted colocalization coefficients calculated from confocal images of immunostained transgenic (*oxt*:gal4; UAS:Syp-EGFP) larval neurohypophysis.](elife-45650-fig1){#fig1}

To further verify the synaptic identity of the OXT-positive neurohypophyseal axonal swellings, we utilized the transgenic synaptic vesicle reporter, *Tg(UAS:Sypb-EGFP)* ([@bib97]), in combination with a transgenic OXT-specific driver line *Tg(oxt:Gal4)* to specifically mark OXT synapses ([Figure 1D](#fig1){ref-type="fig"}). This conditional double transgenic line, *Tg(oxt:Gal4;UAS:Sypb-EGFP)* was subsequently subjected to immuno-staining with a specific antibody directed to the mature OXT nonapeptide (cleaved, cyclised and amidated) which is enriched in neurohypophyseal termini ([@bib35]). We observed that almost all the neurohypophyseal anti-OXT immunoreactive puncta co-localized with Synaptophysin-EGFP (Mean weighted colocalization coefficient = 0.87, n = 5 larvae), indicating that mature OXT neuropeptides are located exclusively within neurohypophyseal synaptic axonal swellings ([Figure 1E](#fig1){ref-type="fig"}).

We next visualized and quantified OXT neuropeptide content at the resolution of a single synapse by combining anti-OXT antibody staining with transgenic *Tg(oxt:EGFP)* reporter, mentioned above ([Figure 1F](#fig1){ref-type="fig"}). In this manner, the structure of the synapse itself, labeled by EGFP, could be differentiated from it´s content of oxytocinergic LDCVs, labeled by the anti-OXT antibody. We used image thresholding settings that allowed detection of individual EGFP-labeled synapses and their neuropeptide content, which appeared in the form of immune-reactive OXT puncta that colocalized with these EGFP-labeled synapses ([Figure 1F](#fig1){ref-type="fig"} and [Figure 1---video 1](#fig1video1){ref-type="video"}).

To validate our detection method, we subjected the fish to hypertonic osmotic challenge (25% sea salt) ([Figure 2A](#fig2){ref-type="fig"}), which is known to induce a robust release of oxytocin and vasopressin and, consequently reduced neuropeptide content in the pituitary of both mammals and fish ([@bib6]; [@bib41]; [@bib50]; [@bib68]). We detected several hundreds of synapses and OXT-stained puncta in the neurohypophysis of naïve 8 days post-fertilization (dpf) zebrafish larvae. While the number of these EGFP-positive synapses remained unaltered following acute hypertonic challenge, both the synaptic and OXT puncta volumes were decreased ([Figure 2B--E](#fig2){ref-type="fig"}). Recovery of larvae from hypertonic to isotonic condition (for 1 hr) led to partial-reversal of the observed phenotypes ([Figure 2C and E](#fig2){ref-type="fig"}). These results are in agreement with the reported hypertonicity-induced cell shrinking mechanisms essential for osmosensation in these neurons ([@bib70]).

![Osmotic challenge decreases synaptic OXT neuropeptide content.\
(**A**) Transgenic Tg(*oxt*:EGFP) larvae at eight dpf were treated with hypertonic solution (25% artificial sea salt in Danieau buffer) for 20 or 60 min. The larvae that underwent 60 min treatment were allowed to recover in isotonic Danieau buffer for another 60 min. The mean number and volume of NS (**B,C**) and OXT puncta overlapping with GFP +NS (**D,E**) were quantified (\*\*p\<0.01 and \*\*\*p\<0.001; one-way ANOVA). (**F--J**) Cell-specific blockage of synaptic release using botulinum toxin light chain B increases hypophyseal OXT levels (**F**). The mean number and volume of mCherry +NS (**G,H**) and oxytocin puncta overlapping with mcherry +NS (**I,J**) were quantified in 8-dpf old larvae of Tg(*oxt*:Gal4; UAS:NTR-mCherry) labeled as BoTx- (n = 13 larvae) versus Tg(*oxt*:Gal4; UAS:BoTxLCB-GFP; UAS:NTR-mCherry) at isotonic Danieau buffer (BoTx+ (n = 14 larvae)) or upon 60 min treatment with hypertonic solution (ST BoTx+; n = 12 larvae). (\*\*\*p\<0.001, \*\*\*\*p\<0.0001; one-way ANOVA). Error bars indicate SEM in (B-E and G-J).\
10.7554/eLife.45650.006Figure 2---source data 1.Experimental data for [Figure 2](#fig2){ref-type="fig"}: Neurohypophyseal synaptic parameters upon hyperosmotic challenge.The excel sheet includes values for number and volume of neurohypophyseal synapses and OXT puncta upon hyperosmotic challenge.](elife-45650-fig2){#fig2}

To further validate our method, we utilized a conditional triple transgenic line *Tg*(*oxt:Gal4; UAS:NTR-mCherry; UAS:BoTxLCB-GFP*) for OXT neurons-specific expression of botulinum toxin, which cleaves the vesicle-associated membrane protein (VAMP) thereby inhibiting LDCVs synaptic release. In this transgenic line, synaptic vesicle release from OXT neurons was blocked due to intracellular expression of botulinum toxin light chain B (BoTxLCB) fused to EGFP ([@bib81]) and OXT synapses were visualized via mCherry ([Figure 2F](#fig2){ref-type="fig"}). OXT-specific expression of BoTxLCB led to increased volume of OXT puncta, but without affecting the number and volume of the synapses, indicative of accumulation of OXT content ([Figure 2G--J](#fig2){ref-type="fig"}). The increased synaptic OXT level we observed in BoTxLCB transgenic larvae under naïve conditions, was maintained following hypertonic challenge. These results suggest that both basal OXT release and hypertonic osmotic challenge- induced OXT release are blocked by expression of BoTxLCB. We conclude that the above methodology can faithfully quantify synaptic OXT neuropeptide content in vivo.

Disruption of F-actin affects synaptic OXT neuropeptide content {#s2-2}
---------------------------------------------------------------

As mentioned above, recent studies reported that dynamic changes in synaptic actin regulates multiple aspects of vesicular homeostasis. To study the spatial relationship between actin and synaptic OXT neuropeptide we performed super-resolution microscopy of a double transgenic line, *Tg(oxt:Gal4; UAS:Lifeact-EGFP)*, in which the filamentous actin (F-actin) probe, Lifeact-EGFP, was specifically expressed in OXT neurons. *Tg(oxt:Gal4; UAS:Lifeact-EGFP)* larvae were immunostained with antibodies against EGFP and endogenous OXT and imaged using stochastic optical reconstruction microscopy (STORM) ([Figure 3A--D](#fig3){ref-type="fig"}). Imaging revealed various characteristics of actin and neuropeptides. Lifeact-EGFP signal exhibited a cage-like structure surrounding OXT in neurohypophyseal synapses ([Figure 3B--D](#fig3){ref-type="fig"} and [Figure 3---video 1](#fig3video1){ref-type="video"}). These results are in agreement with previous reports that actin filaments form a cage-like structure associated with synaptic vesicles ([@bib39]; [@bib58]).

![Actin polymerization regulates synaptic OXT content.\
(**A--D**) Spatial relationship between actin and neuropeptide in hypophysis revealed by super-resolution microscopy. Stochastic optical reconstruction microscopy (STORM) images of the neurohypophyseal area of 6 days post-fertilization (dpf) Tg(*oxt*:gal4; UAS:lifeact-EGFP) larvae stained using anti-OXT and anti-GFP antibodies (**A**). (**B--D:**) Magnifications of squared areas. Scale bars: 1 µm. (**E--H**) Assessment of the effect of cytochalasin D treatment on synaptic properties in Tg(*oxt*:EGFP) larvae. Larvae were treated with DMSO or cytochalasin D at 400 nM between 4 and 5 dpf, stained using anti-GFP and anti-OXT antibodies and quantified following imaging as in [Figure 1](#fig1){ref-type="fig"}. The number and mean volume of neurohypophyseal synapses (NS) (**E,F**) and the number and mean volume of NS-associated OXT puncta (**G,H**) was quantified. p\<0.01, Student's *t*-test, Cohen's d = 1.54 (**E**); p\<0.1, Student\'s t-test, Cohen\'s d = 0.85 (**F**); p\<0.05, Student\'s t-test, Cohen\'s d = 1.17 (**G**); p\<0.01, Student\'s t-test, Cohen\'s d = 1.43 (**H**), n = 8, 12 for DMSO and cytochalasin D treatment, respectively. (**I--N**) Assessment of the effect of oxytocin-neuron specific perturbation of actin. Transgenic embryos expressing the oxytocin Gal4 driver (*oxt*:Gal4) were injected with transposon-based transgenic vectors containing either control UAS:EGFP (**I**) or UAS:Cofilin-EGFP (**L**) expression cassettes. All the injected larvae were sorted for fluorescent heart selection marker and were subjected to immunostaining with anti-EGFP and anti-OXT antibody. 5-dpf larvae with and without expression of EGFP-labeled neurohypophyseal synapses were imaged using confocal microscopy as in [Figure 1F](#fig1){ref-type="fig"}. The number (**J,M**) and volume of OXT puncta (**K,N**) were quantified. (J-M: ns, non-significant; N: p\<0.05; Student's t-test with Cohen's d = 0.92). Error bars indicate SEM in (E-H, J,K,M and N).\
10.7554/eLife.45650.008Figure 3---source data 1.Experimental data for [Figure 3](#fig3){ref-type="fig"}: Neurohypophyseal synaptic parameters upon actin perturbation.The excel sheet includes values for number and volume of neurohypophyseal synapses and OXT puncta from confocal imaging of larvae that were subjected to DMSO vs cytochalasin treatment or embryos that underwent transgenesis experiment for OXT-neuron specific EGFP vs cofilin expression.](elife-45650-fig3){#fig3}

As Lifeact can also bind monomeric actin and it's binding to F-actin can be affected by the presence of specific actin regulators such as cofilin ([@bib22]), we undertook two alternative pharmacological and genetic approaches to link actin polymerization to synaptic OXT content. We first perturbed the actin filaments by using the actin depolymerizing agent cytochalasin D ([@bib21]). Transgenic Tg(*oxt*:EGFP) larvae were treated with cytochalasin D between 4 and 5 days post-fertilization at a concentration of 400 nM, which is a tolerated dose that allows normal development and viability of zebrafish larvae ([@bib85]). Subsequent analysis revealed that the number and size of the synaptic axonal swellings was reduced upon cytochalasin D treatment ([Figure 3E,F](#fig3){ref-type="fig"}), which is in agreement with the involvement of F-actin in regulating the synaptic morphology ([@bib99]). Cytochalasin D treatment also affected both the number and volume of OXT puncta ([Figure 3G,H](#fig3){ref-type="fig"}).

As an alternative approach to test the role of actin dynamics, we expressed the Cofilin-EGFP fusion protein using the *Tg(oxt:Gal4)* transgenic driver, which allowed manipulation of the actin polymerization specifically in oxytocinergic neurons. Cofilin is a member of ADF family of actin-binding proteins that promote F-actin depolymerizing and regulates its turnover ([@bib77]; [@bib89]). The effects of Cofilin on OXT synapses was tested by co-injecting transposon-based DNA constructs harboring *oxt*:Gal4 together with either UAS:Cofilin-EGFP or UAS:EGFP construct as a control and thereafter monitoring OXT levels in either EGFP- or Cofilin-EGFP- positive compared to EGFP-negative OXT synapses. We observed that expression of control EGFP alone did not affect number and volume of OXT puncta however, expression of Cofilin-EGFP led to decreased OXT puncta volume ([Figure 3I--N](#fig3){ref-type="fig"}) with a large effect size of Cohen's d of 0.93, p-value\<0.05 ([@bib20]). Together, the above results suggest that actin polymerization regulates synaptic OXT neuropeptide content.

Robo2 regulates synaptic actin dynamics {#s2-3}
---------------------------------------

Next, we searched for candidate signaling pathways that could regulate axonal F-actin in OXT neurons. Robo2 is localized to axonal growth cones and is known to regulate axonal guidance by modulating actin dynamics via other actin interacting regulatory proteins ([@bib44]; [@bib78]). Fluorescent in situ hybridization of *robo2* mRNA showed that it is expressed in OXT neurons ([Figure 4A](#fig4){ref-type="fig"}). To investigate if Robo2 regulates synaptic actin dynamics, we used the zebrafish *robo2-*deficient mutant, *astray* \[*robo2*^272z/272z^ ([@bib29]), and performed fluorescence recovering after photobleaching (FRAP) on individual OXT synapses expressing the F-actin sensor *Tg(oxt:Gal4;UAS:Lifeact-EGFP)* in either *robo2+/+* or *robo2-/-* animals ([Figure 4B,C](#fig4){ref-type="fig"}). We reasoned that the dynamics of Lifeact-EGFP fluorescence recovery indicates changes in synaptic polymerized actin, which is available for Lifeact-EGFP binding. Thus, it is expected that synapses wherein actin filaments are highly stable would display an increased time of Lifeact-EGFP fluorescence recovery. Indeed, in comparison to the *robo2*+/+ zebrafish, the recovery of Lifeact-EGFP fluorescence was attenuated in OXT synapses of *robo2*-/- mutants ([Figure 4D](#fig4){ref-type="fig"}), which exhibited decreased dynamic Lifeact-EGFP fraction and increased stable fraction ([Figure 4E,F](#fig4){ref-type="fig"}; Cohen's d effect size 0.67, *p* value \< 0.05.) This suggests that Robo2 signaling regulates synaptic actin dynamics of neurohypophyseal OXT neurons.

![Robo2 regulates synaptic actin dynamics.\
(**A**) *robo2* is expressed in larval zebrafish neurosecretory preoptic area (NPO) and colocalizes with Oxytocin neurons. Confocal Z-stack images showing fluorescent in situ hybridization (FISH) of transgenic larvae Tg(*oxt*:EGFP) (3 days post-fertilization (dpf)) using probes directed against *robo2* mRNAs (magenta), followed by anti-EGFP staining. The neurosecretory preoptic (NPO) area in which OXT neurons were labeled is shown. Scale bar: 20 µm. (**B,C**) Real-time monitoring of synaptic actin dynamics in live transgenic reporter Tg(*oxt*:Gal4; UAS:Lifeact-EGFP) larvae mounted in 0.1% low-melt agarose and imaged using multi-photon microscopy upon Fluorescence Recovery after Photobleaching (FRAP) (**B**). Time-series images of FRAP experiment in a neurohypophyseal synapse with Lifeact-EGFP expression (**C**). Scale bar: 200 nm. (**D--F**) Assessment of synaptic actin dynamics in *robo2* mutant using the transgenic actin dynamics reporter Tg(*oxt*:Gal4; UAS:Lifeact-EGFP) larvae. Graph showing the normalized FRAP profile of Lifeact-EGFP fluorescence intensity in 6-dpf *robo2*+/+ (n = 19 synapses from seven larvae) and *robo2*-/- (n = 21 synapses from seven larvae) (**D**) (\*\*\*p\<2e-16) for genotypeXtime interaction effect in a linear mixed effects model to account for inter-synapse and inter-genotype variability (see Materials and methods). Bar graphs showing the dynamic (**E**) and stable (**F**) Lifeact-EGFP fractions in *robo2*^+/+^ vs *robo2*^-/- ^neurohypophyseal synapses (\*p\<0.05 Student's *t*-test; with Cohen's d = 0.67). Error bars indicate SEM in (**D--F**).\
10.7554/eLife.45650.011Figure 4---source data 1.Experimental data for [Figure 4](#fig4){ref-type="fig"}: Actin dynamics in neurohypophyseal synapses.The excel sheet includes values for FRAP data of neurohypophyseal synaptic Lifeact-EGFP in robo2 +/+ vs robo2 -/- larvae. The full-scale normalized values, dynamic and stable fraction generated from Easy-Frap software are shown.](elife-45650-fig4){#fig4}

Slit3-Robo2 signaling regulates synaptic OXT content {#s2-4}
----------------------------------------------------

We next asked if Robo2 plays a role in synaptic accumulation of OXT by examining whether neurohypophyseal neuropeptide content is altered in the *robo2-*defiecient mutant zebrafish. We found that the volume of OXT puncta was smaller in *robo2*-/- fish compared to WT controls with a large effect size (Cohen's d of 0.82, p value\<0.05), while the number and size of neurohypophyseal synapses were largely unaffected, suggesting that Robo2 regulates synaptic oxytocin levels without affecting synaptic morphogenesis ([Figure 5A--D](#fig5){ref-type="fig"}). This phenotype was not due to OXT axonal guidance deficits, as the number of neurohypophyseal OXT axonal projections was similar between *robo2-/-* and *robo2+/+* fish larvae ([Figure 5E](#fig5){ref-type="fig"}).

![Slit3-Robo2 signaling regulates synaptic OXT levels.\
(**A--E**) Assessment of synaptic oxytocin content in *robo2* mutant was performed as described in [Figure 1F](#fig1){ref-type="fig"}. Graph showing the number and size of neurohypophyseal synapses (NS) (**A,B**) and colocalizing OXT puncta (**C,D**) and the number of neurohypophyseal projecting axons (**E**) in 8 days post-fertilization (dpf) *robo2*+/+ (n = 13) vs *robo2*-/- (n = 17) larvae (\*p\<0.05 Student's *t*-test with Cohen\'s d = 0.82; ns denotes not significant). (**F--J**) Assessment of synaptic oxytocin content upon *slit3* knock-down. Transgenic (*oxt*:EGFP) embryos were injected with injection buffer or injection buffer with 0.85 ng of morpholino targeted to the translational start site of *slit3*. Graph showing the number and size of NS (**F,G**) and colocalizing OXT puncta (**H,I**) and the number of neurohypophyseal projecting axons (**J**) in 8 days post-fertilization (dpf) control (n = 15) vs slit3 morpholino injected (n = 14) larvae (\*\*p\<0.05 with Cohen's d = 1.23; ns denotes not significant, Student's *t*-test). (**K**) Hypophyseal POMC cells are localized near OXT synapses. Confocal Z-stacks maximum intensity projection of hypophysis region of 5 day old triple transgenic (*pomc*:EGFP; *oxt*:Gal4; UAS:NTR-mCherry). The hypophysis area showing OXT NS adjacent to anterior and posterior clusters of POMC cells are shown. Scale: 10 μM. (**L--R**) Local overexpression in mosaic hypophyseal POMC clones located. Transgenic embryos expressing the *pomc*:Gal4 driver were injected with transposon-based transgenic vectors containing either control UAS:tRFP (**M,P**) or UAS: Slit3-EmGFP (**N,Q**). The injected 5-dpf larvae were subjected to immunostaining with anti-OXT protein and anti-GFP. OXT-puncta (arrows) within a distance of 2 μM (yellow dashed ellipse) from the clone surface were quantified. Scale bar: 2 µm. Bar graphs showing the mean volume of OXT puncta upon expression of tRFP vs Slit3 in hypophyseal POMC anterior (n = 15 and 18, respectively) or posterior clone (n = 10 and 10, respectively) position (\*p\<0.05 Student's *t*-test with Cohen's d = 1.14). Error bars indicate SEM in (A-J, O and R).\
10.7554/eLife.45650.013Figure 5---source data 1.Experimental data for [Figure 5](#fig5){ref-type="fig"}: Neurohypophyseal synaptic parameters upon gain- or loss-of function of *slit3* or *robo2*.The excel sheet includes values for number and volume of neurohypophyseal synapses and OXT puncta from confocal imaging of larval neurohypophysis of multiple experiments namely: 1) robo2 +/+ vs robo2 -/- 2) Mock vs morpholino-injected embryos 3) Mosaic transgenesis experiments by hypophyseal expression of tRFP vs slit3.](elife-45650-fig5){#fig5}

We recently identified that *slit3*, a cognate ligand for Robo2 is highly expressed in the developing neurohypophysis ([@bib2]). We performed genetic gain/loss-of-function experiments to study the role of Slit3 in regulating synaptic OXT content. Knock-down of *slit3* using a previously validated morpholino antisense oligonucleotide targeted to the translational start site ([@bib7]), led to reduced synaptic OXT content similar to the *robo2* mutant phenotype ([Figure 5F--J](#fig5){ref-type="fig"}). Thus, the volume of OXT puncta was significantly reduced following *slit3* knockdown, compared to mock injected controls (Cohen's d effect size 1.12, *p* value \< 0.01), while the number, size of neurohypophyseal synapses and number of neurohypophyseal OXT axonal projections were unaffected. To investigate the role of Slit3 locally, we employed the *Tg(pomc:Gal4)* driver that enabled local secretion of Slit3-EmGFP fusion protein from proopiomelanocortin (POMC) cells that are arranged in two clusters, anterior and posterior, abutting neurohypophyseal OXT axons and synapses respectively ([Figure 5K](#fig5){ref-type="fig"}). We generated mosaic transgenic clones expressing Slit3-EmGFP in anterior and posterior hypophyseal locations ([Figure 5L](#fig5){ref-type="fig"}). Interestingly, when comparing to tRFP expressing clones we detected enlarged volume of OXT puncta adjacent to Slit3-EmGFP-positive clones located in a posterior but not anterior position ([Figure 5M--R](#fig5){ref-type="fig"}). As depicted schematically in [Figure 5L](#fig5){ref-type="fig"}, this localized effect of Slit3 coincided with the posterior position of the endogenous OXT synapses. These results suggest that localized context-dependent Slit3-Robo2 signaling regulates synaptic OXT levels.

Robo2 regulates synaptic OXT vesicles accumulation {#s2-5}
--------------------------------------------------

We next asked if Robo2 plays a role in synaptic accumulation of OXT-loaded vesicles. To visualize OXT neuropeptide dynamics in real time, we developed a novel transgenic tool, *Tg\[oxt:OXTSP-EGFP-OXT-NP\]*, in which OXT promoter drives the expression of EGFP fused with the OXT precursor, between the signal sequence and the OXT peptide ([Figure 6A](#fig6){ref-type="fig"}). Efficient production of a cleaved EGFP-OXT fusion protein was confirmed by Western blot analysis of pituitary synaptosomes isolated from adult pituitaries of transgenic fish ([Figure 6B](#fig6){ref-type="fig"}). The vesicular synaptic expression of the EGFP-OXT fusion protein was validated by triple co-immunostaining of the transgenic EGFP-tagged product, together with two specific antibodies to the endogenous neurophysin and OXT nonapeptide. This revealed that the EGFP-tagged OXT transgenic protein product mainly co-localized with the mature (i.e. cleaved and cyclised) endogenous OXT neuropeptide ([Figure 6C](#fig6){ref-type="fig"} and [Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). As expected, in some cases, the OXT-GFP reporter protein co-localized with vesicles containing both cleaved and OXT-neurophysin protein, suggesting that it reported an intermediate step in the proteolytic processing of the OXT precursor peptide ([Figure 6C](#fig6){ref-type="fig"}). To verify the vesicular synaptic localization of the EGFP-tagged OXT we performed super-resolution microscopy (STORM) imaging of *Tg\[oxt:OXTSP-EGFP-OXT-NP\]* larvae. Our results showed that similar to the endogenous OXT, the EGFP-OXT reporter exhibited a clustered organization, indicative of large dense core vesicular organization of OXT ([Figure 6D,E](#fig6){ref-type="fig"} and [Figure 6---video 1](#fig6video1){ref-type="video"}). To detect F-actin co-localization with EGFP-OXT labeled vesicles in neurohypophyseal synapses, we used the Calponin domain of Utrophin fused to mCherry (UAS:mCherry-Utrophin-CH), which is a specific F-actin probe ([@bib56]). We expressed mCherry-Utrophin-CH in OXT neurons in combination with our Tg(*oxt*:oxt-SP-EGFP) that labels OXT-loaded vesicles in synapses and found that mCherry-Utrophin-CH co-localizes with OXT-loaded synaptic vesicles ([Figure 6F](#fig6){ref-type="fig"}). This result further supports our original suggestion that that F-actin is enriched near OXT synaptic vesicles.

![Robo2 regulates synaptic OXT dynamics.\
(**A**) Schematic of novel transgenic OXT tool Tg(*oxt*:OXT-SP-EGFP-OXT), in which *oxt* promoter drives expression of Oxytocin precursor protein with an internally-tagged EGFP at the C-terminus of the signal peptide. (**B**) Validation of OXT-fusion EGFP protein expression by Western blot analysis. Pituitary protein extracts from adult Tg(*oxt*:OXT-SP-EGFP-OXT), TL (control) and Tg(*oxt*:EGFP) zebrafish were immunoblotted using anti-GFP. (**C**) Validation of OXT-fusion EGFP protein expression by immunohistochemistry. Confocal Z-stack images of the neurohypophyseal area of 5-dpf transgenic Tg(*oxt*:OXT-SP-EGFP-OXT) larvae. Larvae were stained using anti-GFP, anti-OXT and anti-neurophysin antibodies. Scale bar: 5 µm. (**D--E**) Assessment of endogenous vs OXT-fusion EGFP protein localization and packaging by super-resolution microscopy. STORM Z-stack images of the endogenous synaptic OXT (**D**) in comparison to OXT-EGFP fusion in transgenic Tg(*oxt*:OXT-SP-EGFP-OXT) larvae (**E**). five dpf larvae were stained with either anti-OXT (**D**) or anti-GFP (**E**) antibodies and visualized by STORM as described in the Method section. The right panels D' and E' show magnifications of the represented areas outlined in **D**) and **E**) Scale bars: 1 µm. Color code indicates Z-axis depth. (**F**) Spatial relationship between F-actin and OXT-fusion EGFP neuropeptide in hypophysis. Tg(*oxt*:OXT-SP-EGFP-OXT) embryos expressing the OXT-fusion were injected with transposon-based transgenic vectors Tg(oxt:Gal4) and Tg(UAS:mCherry-Utrophin-CH) expression cassettes. Confocal Z-stack images of the neurohypophyseal area of 5-dpf transgenic larvae (**F**). Maginification showing the EGFP-positive synapses and Utrophin-labeled mCherry-positive F-actin in the synapse (**F'**). Scale bars: 1 µm. (**G,H**) Real-time monitoring of synaptic oxytocin vesicle dynamics in live transgenic reporter Tg(*oxt*:OXT-SP-EGFP-OXT) larvae. Schemata of the experimental design (**G**): six dpf larvae were mounted dorsally in low-melt agarose gel, submerged in E3 embryo buffer and imaged using multi-photon microscopy. Neurohypophyseal synapses containing OXT-EGFP vesicles were photobleached and the fluorescence recovery after photo bleaching (FRAP) over time was monitored. The fluorescent recovery occurs due to the dynamic exchange of mobile and unbleached OXT-EGFP vesicles from neighboring *en passant* synapses over time (t = 1--5 min). The brightness and contrast of the images were increased to visualize the individual pixels (**H**). Scale bar: 200 nm. (**I**) Graph showing neuropeptide accumulation (normalized FRAP curves) of OXT-EGFP in neurohypophyseal synapses in 6-dpf *robo2*+/+ (n = 9 larvae) vs robo2-/- (n = 6 larvae) (\*\*\*p\<2.76e-05) for genotypeXtime interaction effect in a linear mixed effects model to account for inter-synapse and inter-genotype variability (see Materials and methods). Neuropeptide accumulation represents full scale normalized data to account for differences in synaptic OXT-EGFP fluorescence, that is fluorescent values upon photobleaching were normalized to zero. Error bars indicate SEM.\
10.7554/eLife.45650.016Figure 6---source data 1.Experimental data for [Figure 6](#fig6){ref-type="fig"}: OXT-EGFP dynamics in neurohypophyseal synapses.The excel sheet includes values for FRAP data of neurohypophyseal synaptic OXT-EGFP in robo2 +/+ vs robo2 -/- larvae. The full-scale normalized values generated from Easy-Frap software are shown.](elife-45650-fig6){#fig6}

To assess the vesicular mobility and monitor in vivo neuropeptide homeostasis using our novel transgenic OXT vesicles reporter, we performed FRAP analysis of individual neurohypophyseal synapses using two-photon microscopy in live 6 days post-fertilization transgenic *Tg\[oxt:OXTSP-EGFP-OXT-NP\]* larvae ([Figure 6G](#fig6){ref-type="fig"}). Upon bleaching, we observed gradual recovery of EGFP-OXT fluorescence indicating the mobilization of transiting OXT-loaded vesicles in the synapses. The extent of fluorescence recovery was low (13%), suggesting that the majority of the bleached OXT-EGFP-positive vesicles were stationary and not mobile ([Figure 6H,I](#fig6){ref-type="fig"}). FRAP analysis in transgenic larvae on the background of *robo2* mutants revealed that the fluorescence recovery rate in *robo2*-/- mutants, was significantly lower than in *robo2*+/+ larvae ([Figure 6I](#fig6){ref-type="fig"}). Taken together, these results suggest that Robo2-mediated signaling regulates actin dynamics as well as the accumulation of OXT-containing vesicles in neurohypophyseal synapses.

Robo2 and Cdc42 regulate OXT neuropeptide levels {#s2-6}
------------------------------------------------

We hypothesized that Robo2 exerts its effect on OXT content via actin polymerization; thus we searched for a candidate signaling mediator that could link between these two Robo2-mediated effects on actin dynamics and OXT content. Robo signaling is known to affect the transition of the Rho-GTPase protein Cdc42 from GTP- to GDP- bound state, resulting in decreased actin polymerization ([@bib94]). We therefore tested if conditional OXT-specific expression of dominant-negative (i.e. GDP-bound) mutant form of CDC42, termed Cdc42(T17N), would affect synaptic OXT content and whether the effect would be dampened in a Robo2 mutant. We used our *Tg(oxt:Gal4)* transgenic fish to drive specific oxytocinergic expression of EGFP-Cdc42(T17N) fusion protein, which was regulated by ten Gal4 DNA binding UAS repeats ([@bib4]). Thus, one cell-stage embryos were co-injected with transposon-based DNA constructs harboring *oxt*:Gal4 together with either UAS:EGFP-Cdc42-T17N or UAS:EGFP construct as a control. ([Figure 7A](#fig7){ref-type="fig"}). We then quantified the levels of OXT and EGFP-Cdc42(T17N) proteins in each synapse ([Figure 7B](#fig7){ref-type="fig"}). We took advantage of the variable expression of the injected construct in each individual synapse, to examine whether differences in OXT content correlated with expression levels of EGFP-Cdc42(T17N) or the control EGFP. Regression analysis of OXT fluorescence as a function of EGFP fluorescence in each injected zebrafish larvae showed that high EGFP fluorescence led to decreased OXT levels in both *robo2+/+* and *robo2-/-* larvae ([Figure 7C](#fig7){ref-type="fig"}; p\<0.01, adj. R^2^ = 0.93 and 0.85 respectively) ([Figure 7C](#fig7){ref-type="fig"}). This effect is likely due to overexpression of the untethered EGFP. In contrast, expression levels of EGFP-Cdc42(T17N) were positively correlated with increased OXT content in *robo2+/+* ([Figure 7D](#fig7){ref-type="fig"}; p\<0.01, adj. R^2^ = 0.74). However, the positive effect of EGFP-Cdc42(T17N) on synaptic OXT content was dampened in *robo2-/-* mutants ([Figure 7D](#fig7){ref-type="fig"}; p=0.35, Adj. R^2^ = 0.52), a finding which is consistent with the fact that Robo2 inactivation leads to increased levels of active GTP-bound Cdc42, which may counteract Cdc42(T17N). In contrast to the aforementioned effect of dominant-negative EGFP-Cdc42(T17N) mutant protein, overexpression of EGFP-fused constitutively-active (i.e. GTP-bound) mutant form of CDC42, termed Cdc42(G12V), led to a dose-dependent decreased OXT levels in EGFP positive synapses similar to the low OXT levels in *robo2 -/-* synapses ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). These results place the small GTPase Cdc42, which is a key regulator of actin dynamics, in a Robo2 signaling cascade that controls the levels synaptic OXT neuropeptide ([Figure 7E](#fig7){ref-type="fig"}).

![Robo2 regulates synaptic OXT levels via Cdc42.\
(**A,B**) Assessment of the effect of Oxytocin neuron-specific overexpression of actin-regulating protein Cdc42 in Tg(*oxt*:Gal4) larvae. Transgenic embryos expressing the *oxt*:Gal4 driver were injected with transposon-based transgenic vectors containing either control UAS:EGFP or UAS:Cdc42(T17N)-EGFP. Larvae were fixed at 8 days post-fertilization (dpf) and immunostained with anti-GFP and anti-OXT antibodies and neurohypophyseal synapse (NS) were identified as described earlier. Maximum intensity projection (MIP) reveals mosaic labeling of hypophyseal projecting axons (**B**). Bottom panel show magnifications of squared areas showing single stack with colocalization of axonal swelling with OXT puncta. Scale bar 1 µm. (**C,D**) Linear regression analysis comparing between synaptic EGFP levels (mean EGFP puncta) as a function of OXT fluorescence (mean OXT puncta). The data were normalized using mean-centering approach using the scale function in the 'R' software. Each line represents a regression line of single animal. The correlation between the mean (log~10~) fluorescence value of OXT puncta and GFP expression in neurohypophyseal synapse was tested with a linear regression model (ANCOVA), accounting for the effect of GFP fluorescence, and individual fish. Mean EGFP fluorescence is inversely correlated with OXT fluorescence in *robo2+/+* (n = 5; p\<0.01, adj. R^2^ = 0.93) and in *robo2-/-* (n = 8; and p\<0.01, adj. R^2^ = 0.85) (**C**). Mean EGFP-Cdc42(T17N) fluorescence positively correlates with OXT fluorescence in *robo2+/+* (n = 7; p\<0.01, adj. R^2^ = 0.74) larvae but not in in *robo2-/-* (n = 7; p=0.35, Adj. R^2^ = 0.52) (**D**). (**E**) Model of the role of Robo2 in neurohypophyseal synapses: Synaptic Slit3-Robo signaling inactivates Cdc42 via GAP by affecting the transition of the Rho-GTPase protein Cdc42 from GTP- to GDP- bound state. Cdc42 inactivation reduces actin polymerization and increases synaptic OXT content.\
10.7554/eLife.45650.020Figure 7---source data 1.Experimental data for [Figure 7](#fig7){ref-type="fig"}: Synaptic fluorescence values upon OXT-neuron specific Cdc42 over-expression.The excel sheet includes values for EGFP- and OXT- fluorescence values of neurohypophyseal synapses in larvae that were subjected to OXT-neuron specific EGFP or Cdc42(T17N) or Cdc42(G12V) expression in robo2 +/+ vs robo2 -/-.](elife-45650-fig7){#fig7}

Discussion {#s3}
==========

To maintain body homeostasis, neurons sense and integrate a multitude of environmental and physiological signals and evoke a response when a deviation is detected. To achieve this, neurosecretory synapses of these cells must maintain adequate levels of neuropeptides that are readily primed to be secreted. This is particularly relevant for neuroendocrine signals that occur at the neurohypophysis level where two neuropeptides that are essential for homeostasis, oxytocin and vasopressin are released into the blood circulation to exert their effects on peripheral organs ([@bib60]; [@bib90]). Thus, how neuropeptides homeostasis is maintained in such synapses is a fundamental question.

Recent studies reported that synaptic F-actin regulates multiple aspects of vesicular homeostasis ranging from vesicle capture to release and recycling ([@bib18]; [@bib30]; [@bib34]; [@bib55]; [@bib57]; [@bib79]; [@bib80]; [@bib88]). Actin is also required for recruitment of multiple synaptic proteins and receptors that are essential for synaptic function ([@bib75]). Here, we focused on the neuropeptide OXT, which is stored in LDCVs in numerous axonal swellings. These swellings act as *en passant* synapses, which are highly enriched in neurohypophyseal axonal projections ([@bib62]). We found that local actin dynamics in those synapses regulate the levels of OXT neuropeptide and identified a new signal transduction machinery, Slit3-Robo2-Cdc42, which regulates synaptic actin dynamics to maintain steady-state OXT content in those synapses.

The majority of reported studies on synaptic OXT content and release were performed on organotypic cultures or by electron microscopy on sliced mammalian neurohypophyseal tissues ([@bib1]; [@bib59]; [@bib84]). Using TEM we demonstrated that as in mammals the neurohypophysis of larval zebrafish contains classical neurosecretory synapses that are enriched with electron-dense LDCVs and observed vesicle secretion and recycling events. Consistent with the synaptic identity of OXT-positive neurohypophyseal axonal swellings, nearly all analyzed oxytocin-positive puncta co-localize with a synaptic vesicle reporter Synaptophysin-EGFP. Monitoring synaptic OXT content in the transparent zebrafish larvae, we were able to study the regulation of OXT neuropeptide levels in the context of a living vertebrate animal without invasive manipulation. We demonstrated the robustness and validity of our experimental system by showing that synaptic OXT content is depleted upon osmotic challenge, which is in agreement with previous studies done in mammals and also in teleost fish ([@bib1]; [@bib6]; [@bib64]; [@bib68]). Conversely, expression of the light chain of botulinum toxin serotype B specifically in the OXT neurons, led to increased synaptic OXT content. This is in agreement with the fact that neurohypophyseal neurons exhibit spontaneous activity and activity-dependent SNARE-mediated synaptic release, which is blocked by botulinum toxin ([@bib43]; [@bib83]).

It was reported that dual pools of actin filaments exist in synapses, a cytoplasmic pool associated with the vesicles and a second pool of cortical filaments associated with the plasma membrane ([@bib1]; [@bib10]; [@bib63]). Using super-resolution STORM microscopy of OXT synapses in the Lifeact-EGFP reporter, we observed that actin filaments form cage-like structures that surround OXT-containing vesicles similar to reports in rat neurohypophyseal axonal termini ([@bib1]). The interaction of F-actin with OXT was further reinforced by co-localization of mCherry-Utrophin-CH with OXT-loaded synaptic vesicles. As neuropeptidergic (e.g. OXT) synapses lack active zone, which is typical in small transmitters synapses, the actin cage may regulate vesicle movement and exocytosis. Indeed, synaptic OXT content was decreased upon treatment of zebrafish larvae with cytochalasin D, a cell permeable mycotoxin known to inhibit F-actin formation ([@bib21]; [@bib31]; [@bib51]).

Synaptic actin filaments are dynamic structures which undergo treadmilling and regulate synaptic morphogenesis ([@bib12]; [@bib40]). Using FRAP analysis of the actin probe Lifeact-EGFP in OXT synapses of live animals, we found that synaptic Lifeact-EGFP dynamics is perturbed in *robo2* mutants. Thus, *robo2* mutants exhibit reduced mobile Lifeact-EGFP fraction and increased stable fraction, which was correlated to reduced OXT content in those synapses. It should be noted that using Lifeact-EGFP has several drawbacks including binding monomeric G-actin and competition with other F-actin binding actin regulators (e.g. Cofilin). Further experiments using FRAP analysis of Actin-EGFP, should be used to support our interpretation that the dynamics of synaptic polymerized actin is altered in *robo2* mutants. Having said that, a direct requirement of actin polymerization in OXT synapses was further supported by our finding that synaptic OXT content was reduced upon expression of actin depolymerizing protein Cofilin ([@bib77]; [@bib89]), specifically in the OXT neurons. Notably, it was reported that Cofilin affects synaptic plasticity and morphology ([@bib42]; [@bib52]; [@bib67]; [@bib69]; [@bib100]) however, we did not observe any gross changes in the number or size of the OXT synapses, indicative of the specificity of our genetic manipulations. As cofilin-dependent actin dynamics has been reported to function in synaptic vesicle mobilization and exocytosis ([@bib93]), it may play a similar role in OXT synapses.

We recently identified that *slit3*, a cognate ligand for Robo receptors is highly expressed in pituicytes, the astroglial component of the neurohypophysis directly contacting OXT termini ([@bib2]). In addition to axonal guidance, Robo-Slit signaling is also known to regulate synaptogenesis and actin dynamics in other CNS regions ([@bib11]; [@bib17]; [@bib44]; [@bib78]). However, the role of Robo-Slit3 in OXT synapse formation and function is not known. We show here that Robo2 is expressed in OXT neurons and genetic perturbations of both *slit3* and *robo2* affect synaptic OXT content. Notably, previous studies have shown that Slit-Robo signaling regulates actin dynamics during neuronal migration and axonal guidance ([@bib44]; [@bib78]; [@bib94]). However, the reduction in synaptic OXT content, which we observed in *robo2* -/- mutants and following *slit3* knockdown were not accompanied by axon guidance defects as the number of neurohypophyseal projecting axons were unaffected.

In view of our findings regarding the involvement of Robo2 in synaptic actin dynamics and OXT content, we hypothesized that changes in synaptic actin mobility regulate the steady-state accumulation of OXT-containing vesicles at the neurohypophyseal release site. To directly test this hypothesis, we established a novel transgenic zebrafish OXT-EGFP fusion line, allowing real time in vivo monitoring of the dynamicity of OXT-loaded vesicles. Notably, transgenic rats harboring a similar OXT-EGFP fusion have already been reported ([@bib36]); however, the deep anatomical location of the neurohypophysis makes it difficult to study the dynamic sub-cellular processes in mammalian species in vivo. Using our zebrafish transgenic reporter, we observed that the majority of the vesicles were immobile, as only 13% of non-bleached fluorescent vesicles exchanged into the photobleached synapses. This finding is in agreement with previous work on LDCV mobility in Drosophila neuroendocrine termini ([@bib14]). We revealed that Robo2 regulates the accumulation of transiting OXT-loaded vesicles in the synapses. Whether this phenotype is due to decreased vesicle capture or increased exocytosis needs to be further investigated. As Robo2 and Slit3 are also involved in inhibition of dopamine secretion in the midbrain and insulin secretion in pancreatic cells ([@bib33]; [@bib96]), they might also function to inhibit synaptic OXT release and associated excitation-secretion coupling observed in these neurons ([@bib48]).

To link synaptic actin dynamics to Robo2 signaling and regulation of neuropeptide content we targeted the intercellular GTPase Cdc42, which acts downstream of Robo signaling pathway to affect actin dynamics. During neuronal migration, Robo signaling promotes Cdc42-GTP hydrolysis that, in turn, attenuates actin polymerization ([@bib94]). We show here that expression of the dominant-negative (i.e. GDP-bound) Cdc42(T17N) in OXT synapses led to increased OXT levels in WT fish in a dose-dependent manner while expression of a constitutively-active (i.e. GTP-bound) mutant form of CDC42 had a reciprocal effect. *robo2* mutant was somewhat refractory to the effect of Cdc42(T17N) on synaptic OXT levels, suggesting that Robo2 acts upstream of Cdc42 in the context of synaptic OXT content. These results are consistent with the notion that lack of Robo2 signaling leads to increased levels of GTP-bound Cdc42 ([@bib94]) and reduced synaptic OXT levels (this study). Our findings regarding the regulation of synaptic OXT content might be relevant to other neuropeptidergic and also endocrine cells. Thus, interaction between Cdc42 and vesicle-associated membrane protein 2 (VAMP2) was previously shown in the case of insulin granules in pancreatic beta cells ([@bib65]). These authors suggested that a mechanism whereby glucose activates Cdc42 to induce the targeting of intracellular Cdc42-VAMP2-insulin vesicles to SNARE proteins at the plasma membrane. Notably, OXT, Robo2 and Slit3 have all been implicated in Autism spectrum disorders ([@bib5]; [@bib23]; [@bib53]; [@bib61]; [@bib87]; [@bib98]). Given the nature of neuroendocrine signaling, whereby relatively large quantities of neuropeptides are released in a highly coordinated and temporally controlled manner, it stands to reason that maintaining proper peptide levels at the synapse is crucial for the proper functioning of this system. Thus, further work is required to identify the exact OXT-related neuroendocrine and physiological consequences of impaired Slit3-Robo2-Cdc42 signaling pathway.

Taken together, our findings reveal that Slit3-Robo2-Cdc42 signaling modulates synaptic actin dynamics to maintain steady-state levels of OXT neuropeptide readily primed to be secreted upon physiological demand.

Materials and methods {#s4}
=====================

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                    Designation                                                          Source or\                            Identifiers                                                          Additional\
  (species) or\                                                                                         reference                                                                                                  information
  resource                                                                                                                                                                                                         
  -------------------------------- -------------------------------------------------------------------- ------------------------------------- -------------------------------------------------------------------- -----------------------------------------------------------------------------
  Genetic reagent, TL (D. rerio)   Tg(*oxt*:EGFP)wz01                                                   ([@bib9])                             ZDB-ALT-111103--1                                                    

  Genetic reagent, TL (D. rerio)   Tg(*oxt*:gal4)wz06                                                   ([@bib2])                             ZDB-ALT-171113--2                                                    

  Genetic reagent, TL (D. rerio)   Tg(*oxt*:OXTSP-EGFP-OXT)wz14                                         This manuscript                       ZDB-ALT-181219--3                                                    

  Genetic reagent, TL (D. rerio)   Tg(*UAS*:sypb-EGFP)biu5                                              ([@bib97])                            ZDB-ALT-150115--1                                                    Lior Appelbaum\
                                                                                                                                                                                                                   (Bar-Ilan Univ.)

  Genetic reagent, TL (D. rerio)   Tg(UAS:Lifeact-GFP)mu271                                             ([@bib38])                            ZDB-ALT-130624--2                                                    Wiebke Herzog (Univ. of Muenster)

  Genetic reagent, TL (D. rerio)   Tg(UAS:BotxLCB-GFP)icm21                                             ([@bib81])                            ZDB-ALT-160119--9                                                    Claire Wyart (ICM, Paris)

  Genetic reagent, TL (D. rerio)   Tg(UAS:NTR-mCherry)c264                                              ([@bib25])                            ZDB-ALT-070316--1                                                    

  Genetic reagent, TL (D. rerio)   Tg(−1.0pomca:Gal4-VP16)wz05                                          ([@bib2])                             ZDB-ALT-171113--1                                                    

  Genetic reagent, TL (D. rerio)   *robo2^ti272z^*                                                      ([@bib29])                            ZDB-ALT-980203--1097                                                 Joshua Bonkowsky (Univ. of Utah)

  Recombinant DNA reagent          Tol2 pDEST myl7:mCherry                                              ([@bib32])                                                                                                 Berta Levavi-Sivan, HUJI, Rehovot

  Recombinant DNA reagent          Tol2 10xUAS:EGFP; myl7:mCherry                                       This manuscript                                                                                            Materials and methods - Transgenesis experiments

  Recombinant DNA reagent          Tol2 *oxt*:OXTSP-EGFP-OXT; *myl7*:EGFP                               This manuscript                                                                                            Materials andmethods -Transgenesis experiments

  Recombinant DNA reagent          Tol2 UAS:Cdc42-G12V-EGFP                                             ([@bib4])                                                                                                  Naoki Mochizuki (NCVC, Osaka)

  Recombinant DNA reagent          Tol2 UAS:Cdc42-T17N-EGFP                                             ([@bib4])                                                                                                  Naoki Mochizuki (NCVC, Osaka)

  Recombinant DNA reagent          Tol2 pME mCherry-Utrophin-CH                                         ([@bib3])                                                                                                  Mary Hallaron (Univ. of Wisconsin)

  Recombinant DNA reagent          Tol2 10xUAS:mCherry-Utrophin-CH; myl7:mCherry                        This manuscript                                                                                            Materials and methods - Visualization of synaptic F-actin

  Recombinant DNA reagent          Tol2 pME Slit3(SignalPeptide)-EmeraldGFP-Slit3                       This manuscript                                                                                            Joshua Bonkowsky (Univ. of Utah)

  Recombinant DNA reagent          Tol2 10xUAS: Slit3(SignalPeptide)-EmeraldGFP-Slit3; myl7:mCherry     This manuscript                                                                                            Materials and methods -Transgenesis experiments

  Antibody                         Guinea pig polyclonal, anti-OXT                                      Peninsula labs                        T-5021; RRID:[AB_518526](https://scicrunch.org/resolver/AB_518526)   (1:200)

  Antibody                         Rabbit polyclonal, anti-GFP                                          ThermoFisher                          A11122; RRID:[AB_221569](https://scicrunch.org/resolver/AB_221569)   (1:200)

  Antibody                         Mouse monoclonal, anti-Neurophysin                                   ([@bib8])                             PS45; RRID:[AB_2062089](https://scicrunch.org/resolver/AB_2062089)   Harold Gainer (NINDS, Bethesda)

  Antibody                         Alexa 488- or 647-\                                                  Jackson ImmunoResearch Laboratories                                                                        (1:200) Materials and methods - Immuno-fluorescent staining
                                   Secondary antibodies                                                                                                                                                            

  Antibody                         Alexa 568- or 647-\                                                  Invitrogen                                                                                                 (1:2000)\
                                   Secondary antibodies                                                                                                                                                            Materials andmethods - Visualization of synaptic F-actin

  Chemical compound                Cytochalasin D                                                       Sigma                                 C8273                                                                400 nM

  Chemical compound                Glucose oxidase                                                      Sigma                                 G2133                                                                8440 AU

  Chemical compound                Catalase                                                             Sigma                                 C40                                                                  70200 AU

  Software                         R                                                                    ([@bib71])                                                                                                 Materials and methods -- Statistical analysis

  Software                         Turboreg plugin                                                      ([@bib82])                                                                                                 Materials andmethods -- Statistical analysis

  Software                         EasyFRAP                                                             ([@bib72])                                                                                                 Materials andmethods -- FRAP analysis

  Sequence-based reagent           TATATCCTCTGAGGCTGATAGCAGC                                            Gene Tools, ([@bib7])                 ZDB-MRPHLNO-050927--3                                                Materials andmethods -Transgenesis experiments.\
                                                                                                                                                                                                                   *slit3* knockdown

  Sequence-based reagent           gaatgactcctcgtcgctct and gctgaggcatcttgtctgta                        Sigma                                                                                                      Materials andmethods -Animals. *robo2* genotyping

  Sequence-based reagent           gcatttacaacagctccatc                                                 Sigma                                                                                                      Materials andmethods -Animals.*robo2* sequencing primer

  Sequence-based reagent           tgtacaggcagatgtcaggc and TAATACGACTCACTATAGGG-tcctcctccagtagagccag   Sigma                                                                                                      Materials andmethods - In situ hybridization. PCR primers for *robo2* probe
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Animals {#s4-1}
-------

Zebrafish were raised and bred according to standard protocols. All experimental procedures were approved by the Weizmann Institute\'s Institutional Animal Care and Use Committee (IACUC). Animals were genotyped by Sanger sequencing. Transgenic zebrafish lines Tg(*oxt*:EGFP)^wz01^ ([@bib9]), Tg(*oxt*:gal4)^wz06^ ([@bib2]), Tg(*UAS*:Lifeact-EGFP)^mu271^ ([@bib38]), Tg(*UAS*:BotxLCB-EGFP)^icm21^ ([@bib81]), Tg(UAS:NTR-mCherry)^c264^ ([@bib25]) and *robo2^ti272z^* ([@bib29]) were used in this study.

Transgenesis experiments {#s4-2}
------------------------

We used the Tol2kit transposon-based transgenic vector system for site-specific recombination-based cloning ([@bib47]) and generated all plasmid DNA constructs (See Key Resources Table for list of recombinant DNA reagents). Briefly, genes were cloned into middle entry Tol2 plasmid 218. The DNA sequence of the cloned genes were checked for integrity by DNA Sanger sequencing. The resulting resulting plasmid was cloned downstream of 10xUAS promoter in Tol2 pDEST 395 plasmid with selection marker (green or red heart).

To generate OXTSP-EGFP-OXT construct, EGFP was cloned downstream of signal peptide sequence of zebrafish *oxt* gene (DNA sequence coding for first 20 amino-acids) by overlap extension PCR and cloned into middle entry Tol2 plasmid 218. The resulting plasmid was recombined downstream of *oxt* promoter in Tol2 pDEST 395 plasmid. The resulting plasmid was coinjected with Tol2 transposase mRNA and founders were outcrossed to obtain germline transmitting lines Tg(*oxt*:OXTSP-EGFP-OXT; *myl7*:EGFP)^wz14^.

For *slit3* knockdown by morpholino, morpholino oligonucleotides (MOs) (Gene Tools) targeted to the translation start site of *slit3* were used as described previously ([@bib7]). MO stock was prepared by dissolving it in distilled water at 1 mM and embryos at one-cell stage were micro-injected with ATG-morpholino (0.85 ng/embryo) or mock-injected and allowed to develop at 28.5°C.

For local expression of *slit3*, we performed mosaic transgenesis in POMC+ cells adjacent to axons. Tg(*pomc*:Gal4) embryos at one-cell stage were micro-injected with vector *pomc:Gal4* in combination with 10xUAS:tRFP-caax or 10xUAS:Slit3-emGFP. All the plasmids were injected at concentration of 20 ng/μl each and with transposase mRNA at a concentration of 20 ng/μl (\~500 pl/embryo). Using this method, we were able to attain cell labeling in \~10% of the surviving embryos. 5-dpf larvae that expressed heart marker were collected and fixed in 4% PFA. Due to the mosaic nature of the transgenesis experiments, and sparse labeling of POMC cells in the hypophysis, transgenesis experiments were performed individually.

Hyperosmotic challenge {#s4-3}
----------------------

8 days post-fertilization (dpf) transgenic Tg(*oxt*:EGFP)^wz01^ or Tg(*oxt*:Gal4; UAS:BotxLCB-EGFP; UAS:NTR-mCherry) larvae were treated with 25% artificial sea water (1.75 g Instant ocean Sea salt in 200 mL Danieau buffer) for a period of 60 min and then washed and returned to Danieau's medium for additional 60 min. The larvae were incubated at 28°C during entire procedure and larvae were fixed in 4% PFA overnight at 4°C prior to immunostaining.

Actin perturbation {#s4-4}
------------------

For temporal inhibition of actin filaments, a 100 µM stock of cytochalasin D (Sigma C8273) was prepared in DMSO. Briefly, 15--20 Tg(*oxt*:EGFP) 4-dpf larvae were treated with cytochalasin D (400 nM) for 24 hr in a 12-well plate at 28°C. Control embryos were treated with equivalent concentrations of DMSO.

For specific perturbation of actin in oxytocin neurons, Tg(*oxt*:gal4) embryos were micro-injected with vector *oxt*:gal4 in combination with 10xUAS:EGFP or 10xUAS:cofilin-EGFP or 10xUAS:*cdc42(*T17N)-EGFP or 10xUAS:cdc42(G12V)-EGFP ([@bib4]). All the plasmids were injected at a concentration of 20 ng/μl each and with transposase mRNA at a concentration of 20 ng/μl (\~500 pl/embryo). Using this method, we were able to attain cell labeling in \~10% of the surviving embryos. 8-dpf larvae that expressed the additionally expressed EGFP heart marker were sorted and fixed in 4% PFA prior to immunostaining. Due to the mosaic nature of the transgenesis experiments and sparse labeling of OXT neurons projecting to the hypophysis (\<5% of mosaic clones), transgenesis experiments were performed separately for each constructs.

In situ hybridization {#s4-5}
---------------------

RNA in situ hybridization was performed as described in [@bib54]. For *robo2* probe synthesis, partial coding sequences and 3\' UTR of the genes were amplified by PCR, along with a T7 tail in the reverse primer, and purified with PCR cleanup kit. The purified products served as a template to synthesize digoxigenin-labeled antisense mRNA probes using DIG RNA labeling mix (Roche \#11277073910).

Immunofluorescent staining {#s4-6}
--------------------------

For immunofluorescent staining, PFA-fixed larvae were washed in PBS (2 × 10 min), dehydrated using methanol series (25-50-75--100%) and stored at −20°C overnight. The samples were rehydrated from methanol (75-50--25%) to PBS, washed in PBS-Tx (Triton X100, 0.3%; 2 × 10 min) and blocked in 500 µL of blocking solution (PBS + 10% goat serum +1% DMSO+0.3% Triton X100) for 30 min at room temperature. The solution was then replaced with 200 µL of fresh blocking solution with primary antibodies at 1:200 concentration and incubated overnight at 4°C. Samples were washed with PBS-Tx (3 × 30 min) and treated with 200 µL of secondary antibodies in blocking solution at 1:200 concentration, overnight at 4°C. Then, samples were washed with PBS-Tx (3 × 30 min), transferred to 75% glycerol (25-50--75%) and the jaws were removed using a pair of hypodermic syringe before mounting the larvae with it\'s ventral side facing the objective. Rabbit anti-EGFP (ThermoFisher A11122), Guinea Pig anti-OXT (Peninsula labs T-5021) and secondary antibodies were obtained from Jackson ImmunoResearch Laboratories (West Grove, PA).

Confocal imaging and image analysis {#s4-7}
-----------------------------------

Samples were imaged by using Zeiss LSM 710 or LSM800 confocal microscopes with oil immersion 40X objective. Maximum intensity projection (MIP) images of the whole Z-stacks or subset of Z-stacks were generated using the Zen software (Zeiss). Processing of multiple channel images (i.e., linear adjustments of brightness, contrast and levels) was performed on individual channels using Photoshop CS7 Extended (Adobe). Images were analysed using the open source Fiji image-processing package and Volocity (Perkin Elmer). The number of hypophyseal synapses and OXT puncta was quantified using object measurement tool in Volocity (PerkinElmer) object identifier tool (thresholding was based on SD of fluorescence \>= 4; size of 0.2 to 25 μm^3^). The data were extracted and analysed using R ([@bib71]).

For calculating colocalization coefficient of Syp-EGFP and OXT puncta fluorescence, all the quantitative measurements were conducted on the ZEN black software colocalization module. For each of the scanned larvae (n = 5) an ROI encapsulating the entirety of the hypophysis was manually delineated for each animal. Thresholds were kept at a constant value for all samples, that eliminated most background signal without losing any significant signal originating from stained compartments (17 for the cy5 channel, 15 for the 488 channel). Following this, weighted colocalization coefficients for each channel (M1 and M2), was calculated for each slice in which the hypophyseal synapses was visible (9--10 slices per animal). These values were averaged within each animal to obtain a total mean hypophysis colocalization index for that animal.

Fluorescence recovery after photobleaching (FRAP) and image analysis {#s4-8}
--------------------------------------------------------------------

For live imaging of synaptic Lifeact-EGFP dynamics, 6-dpf live embryos were mounted dorsally in 0.1% low-melt agarose in a 12 mL plate and immersed in Danieau buffer with 0.3% tricaine to prevent movement of the larvae during imaging. The larvae were let to acclimatize for 30 min prior to imaging. FRAP experiments were performed at room temperaturte using Zeiss LSM 2MP multiphoton microscope with 20X water objective of 1.0 numerical aperture and Chameleon Ti-Sapphire laser (Coherent). The acquisition region was 116 × 116 pixels (28.34 µm^2^), and interval between scanning was 0.35 s at a pixel dwell of 1.76 µs. Four circular ROI of 10 × 10 pixels encircling the synapses were selected for each larva, 3 of them for bleach and one for control. Another ROI of similar size was chosen outside the synapses for background quantification. 20 prebleach images were taken and bleach was performed at 75% laser power for 15 iterations and 200 postbleach images were taken.

For live imaging of synaptic OXT-EGFP, embryos were mounted and imaged as described above except for time-lapse parameters. Laser was used at 940 nm 2.5%. The acquisition region was 128 × 64 pixels (14.17 µm x 7.08 µm) and interval between scanning was 1 s at a pixel dwell of 3.15 µs. Two circular ROI of 10 × 10 pixels encircling the synapses were selected for each larva, one for bleach and one for control. FRAP were performed at different Z-stacks covering neurohypophysis. Another ROI of similar size was chosen outside the synapses for background quantification. 20 prebleach images were taken and bleach was performed at 75% laser power and 300 postbleach images were taken. Fluorescence images were drift corrected in Image/Fiji using TurboReg plugin ([@bib82]).

The FRAP values were analysed using EasyFRAP software with full scale normalization to account of difference in synaptic OXT-EGFP fluorescence ([@bib72]). The extracted data were analysed using custom written R-codes (See Statistical Analysis).

Visualization of synaptic F-actin {#s4-9}
---------------------------------

For dual color three-dimensional STORM imaging, 5-dpf Tg(*oxt*:EGFP) or Tg(*oxt*:OXTSP-EGFP-OXT) embryos were immunostained with anti-OXT (1:200) or anti-EGFP (1:200) as described above. For visualization of actin and OXT, Tg(*oxt*:gal4; UAS:Lifeact-EGFP) larvae were fixed and stained with primary antibodies anti-Neurophysin (PS45) and anti-EGFP at 1:200. Secondary antibody (Alexa 647 or 568, Invitrogen) was used at a concentration at 1:2000. Samples were mounted ventrally without the jaws, and soaked in imaging buffer (50 mM 2-mercaptoethanol, 50 mM Tris-HCl (pH 8.0), 10 mM NaCl, 10% (w/v) glucose), 1x Gloxy for 15 min prior to imaging. 50X Gloxy buffer was made by making 8440 AU glucose oxidase (Sigma \#G2133, 50 KU) and 70200 AU catalase (Sigma C40, 100 mg) in 50 mM Tris (pH 8.0) and 10 mM NaCl. Samples were imaged using Vutara SR-200 super-resolution microscope (Bruker). AlexaFluor647 was excited with 640 nm laser (power range of 4--9 kW/cm^2^), AlexaFluor568 was excited with 561 nm laser (6 kW/cm^2^) and 405 nm activation laser power was ramped slowly to maintain optimal single-molecule density. Images were recorded using a 60x, NA 1.2 water immersion objective (Olympus) and Evolve 512 EMCCD camera (Photometrics) with gain set at 50, frame rate at 50 Hz. Total number of frames acquired was 6000 per labeling dye. Data were analyzed by the Vutara SRX software.

To visualize F-actin using an alternate approach, Tg(*oxt*:gal4; *oxt*:OXTSP-EGFP-OXT) embryos were micro-injected with 10xUAS:mCherry-Utrophin-CH at similar conditions mentioned above. 8-dpf larvae were fixed in 4% PFA and imaged using confocal microscopy as mentioned above.

TEM imaging {#s4-10}
-----------

For TEM imaging of the neurohypophyseal axons and synapses, transgenic Tg(*oxt*:EGFP) zebrafish larvae (five dpf) were first anesthetized with tricaine and small incision was made on the dorsal part of the scalp, followed by immediate fixation with fixative buffer (4% PFA, 0.2% glutaraldehyde, 0.1 M cacodylate and 5 mM CaCl~2~) overnight. The fixed larvae were then embedded in 3.4% Noble Agar (DIFCO) and sectioned using vibratome (OTS-4000, Electron Microscopy Sciences, Hatfield, PA). EGFP-positive slices (\~200 µm thick), containing the neurohypophysis were washed in 0.1 M cacodylate buffer and incubated in 1% osmium tetraoxide, 0.5% potassium dichromate, 0.5% potassium hexacyanoferrate in 0.1 M cacodylate for 1 hr. Samples were rinsed in 0.1 M cacodylate and then in double distilled H~2~O. Next, the samples were incubated in 2% uranyl acetate for 1 hr and covered with aluminum foil. Afterwards, samples were dehydrated in ethanol series and infiltrated for 5--7 days at RT in increasing concentration of Epon with ethanol. The Epon-infiltrated samples, were polymerized in at 60°C for 48 hr. Ultrathin sections (60--80 nm) mounted on a mesh grids (Electron Microscopy Sciences, USA) supported with carbon-coated nitrocellulose film. The ultrathin sections double stained with 2% uranyl acetate in ddH2O and Reynolds lead citrate ([@bib73]) and imaged by Tecnai T12 electron microscope operating at 120 kV, utilizing an ES500W Erlangshen CCD camera (Gatan, UK) or an Eagle 2K × 2K CCD camera (FEI).

Western blot {#s4-11}
------------

To validate the expression of OXT-EGFP fusion, adult pituitary of transgenic reporter Tg(*oxt*:SP-EGFP-OXT) were dissected and protein extracts were isolated. As controls, Tg(*oxt*:EGFP) pituitary extracts were isolated. Western blotting was performed on isolated protein extracts using anti-EGFP antibodies at 1:1000.

Statistical analysis {#s4-12}
--------------------

Custom-written R codes were used for analysis of axonal swelling and OXT puncta data. For volume analysis, the values were log-transformed and the mean values were calculated for individual fish. The resulting mean values were back-transformed and statistical test were performed between different genotypes or perturbations. To test for gaussian distribution of the data, Shapiro-Wilk normality test were performed. For comparison of 2 groups, Student's t-test or Mann-Whitney test were performed. For more than 2 groups, ANOVA or Kruskal-Wallis test were performed. Effect size was calculated using Cohen's d test. 

For statistical analyses of FRAP experiments, in order to account the for inter-synapse variability within each animal as well as variability arising from differences between animals both within and between different genotypes (+/+ vs -/-), we generated a linear mixed effects model with time (repeated measure) and genotype as fixed effects, and synapse and fish ID as random effects. Each synapse and each fish were assigned random intercepts.

The correlation between the mean log-transformed (log~10~) fluorescence value of OXT puncta and EGFP axonal swelling was tested with a linear regression model (ANCOVA), accounting for the effect of EGFP axonal swelling, and individual fish.
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10.7554/eLife.45650.021

###### R script for data extraction: R script to extract animal-wise neurohypophyseal synaptic parameters from the Volocity software-derived batch output files.

The script generates tables with parameters such as animal ID, synapse or puncta ID, volume etc. In this manuscript, the script has been used for all the analysis in which number, synaptic OXT content and fluorescence values has been analyzed ([Figures 1](#fig1){ref-type="fig"}--[5](#fig5){ref-type="fig"} and [7](#fig7){ref-type="fig"}).

10.7554/eLife.45650.022

###### R script for data transformation: R script to log-transform the neurohypophyseal synaptic volume data.

In this manuscript, the script has been used for all the analysis in which number, synaptic OXT content and fluorescence values has been analyzed ([Figures 1](#fig1){ref-type="fig"}--[5](#fig5){ref-type="fig"} and [7](#fig7){ref-type="fig"}).

10.7554/eLife.45650.023

###### R script for data analysis: R script to analyze log-transformed neurohypophyseal synaptic data.

The mean number and volume of neurohypophyseal synapse and OXT puncta will be generated upon execution of the script. In this manuscript, the script has been used for all the analysis in which number, synaptic OXT content and fluorescence values has been analyzed ([Figures 1](#fig1){ref-type="fig"}--[5](#fig5){ref-type="fig"} and [7](#fig7){ref-type="fig"}).

10.7554/eLife.45650.024

###### R script for Lifeact-EGFP FRAP data analysis: R script to analyze neurohypophyseal synapse.

Lifeact-EGFP FRAP data by linear-mixed model ([Figure 4D](#fig4){ref-type="fig"}).

10.7554/eLife.45650.025

###### R script for OXT-EGFP FRAP data analysis: R script to analyze neurohypophyseal synapse.

OXT-EGFP FRAP data by linear-mixed model ([Figure 6I](#fig6){ref-type="fig"}).

10.7554/eLife.45650.026

###### R script for correlation analysis: R script to analyze and plot neurohypophyseal synaptic.

EGFP vs OXT fluorescence by linear regression ([Figure 7](#fig7){ref-type="fig"}).

10.7554/eLife.45650.027

Data availability {#s7}
=================

All source data files and codes were uploaded. Source data as summary tables is provided for all graphs and plots shown (Figures 1E; 2B-E and G-J, 3E-H and J,K,M,N, 4D-F, 5O,R, 6I, 7C,D). R codes used for data import and analysis is provided.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

\[Editors' note: this article was originally rejected after discussions between the reviewers, but the authors were invited to resubmit after an appeal against the decision.\]

Thank you for submitting your work entitled \"Robo2 regulates synaptic oxytocin content by affecting actin state\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and a Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: David Murphy (Reviewer \#2).

Our decision has been reached after consultation between the reviewers. Based on these discussions and the individual reviews below, we regret to inform you that your work will not be considered further for publication in *eLife*.

As you can see from the comments enclosed below, all reviewers find your work of interest. However, two of the three reviewers raised substantial issues that, in their opinion, need to be addressed before publication can be considered. After consultation among all reviewers it was agreed that the amount of work required for addressing even only the most important issues exceeds that what can be done in the two months' time period allowed for revision. For these reasons, the reviewers felt that the manuscript cannot be accepted at present.

*Reviewer \#1:*

In the present study, the authors aim at deciphering mechanisms relevant for the function of oxytocinergic synapses. Specifically, they tested whether the Robo2-Cdc42-actin pathway controls oxytocin homeostasis at zebrafish synapses. The authors exploited various transgenic lines and combined live imaging and super-solution microscopy with sophisticated image analyses. They showed a defined spatial distribution of the actin probe Lifeact in oxytocinergic synapses and that manipulation of actin affects the organization of oxytocinergic synapses. Further, they concluded from their experiments that the Robo2-Cdc42 pathway controls F-actin turnover and vesicle mobility in oxytocinergic synapses. Based on my concerns phrased below, some of these conclusions are not valid. Moreover, the rather mild effects reported in several experiments question whether the Robo2-Cdc42 pathway is biologically relevant for oxytocin function.

1\) Throughout the manuscript, most reference literature concerning the presynaptic functions of actin is rather old; definitely, authors have to i) include more recent literature, which reported important novel insights into actin\'s presynaptic functions, and ii) revise their manuscript (Introduction, Discussion) according to the findings reported in these studies.

2\) To prove that BoTxLCB indeed affect oxytocinergic synapses, the hypertonic osmotic challenge paradigm should be performed in the presence of BoTxLCB.

3\) The authors exploited Lifeact in the assumption to specifically probe all F-actin, thereby neglecting several drawbacks of this tool. First, Lifeact is known for its high affinity for monomeric actin. Second, Lifeact\'s binding to F-actin is dependent on the presence of specific actin regulators (e.g. cofilin). Third, high Lifeact levels can affect endogenous F-actin structures. Authors have to include additional approaches to faithfully study the spatial distribution of F-actin in oxytocinergic synapses.

4\) It is not entirely clear to me, which of the data provided led authors to suggest that actin-coated vesicles were associated with the plasma membrane of oxytocinergic synapses? Authors have to include membrane-tagged reporters or a fluorescent volume marker in their experiments.

5\) Based on the aforementioned drawbacks of Lifeact, this probe is not suitable for studying F-actin turnover by FRAP. Authors should instead use GFP-actin, which has been proven to be highly useful to image actin functions in living cells and organisms.

6\) Instead of using a global approach to link actin to the function of oxytocinergic synapses (treatment of larvae with cytochalasin D), authors should consider a genetic approach allowing manipulation of the actin cytoskeleton specifically in oxytocinergic neurons. Cytochalasin D effects on oxytocinergic synapses reported in this study may be rather indirect.

7\) The effects of Robo2 inactivation on Lifeact turnover and oxytocin vesicle mobility a rather low. Although authors found various parameters to be significantly different between controls and Robo2-deficient animals, it is unclear whether Robo2-dependent mechanisms are indeed relevant for oxytocin function and biology. Authors should include additional analyses to tackle this.

*Reviewer \#2:*

Anbalagan and colleagues have use state-of-the-art transgenic and imaging techniques to explore the molecular mechanisms whereby neuropeptides accumulate at synaptic release sites in order to provide the necessary levels required to maintain homeostasis. To do this, they have exploited two tractable models. Firstly, they have focussed on the elaboration of the evolutionarily conserved neuropeptide hormone oxytocin (OXT), which is synthesised as part of the prepropeptide precursor in discrete neurosecretory cells, then processed and transported to release sites in the anatomically distinct neurohypophysis. Secondly, they exploited the optically transparent zebrafish larva to analyse the function of the OXT system at single synapse resolution. The experiments are conceptually well designed, and have been carefully executed. The data produced is robust and aesthetically pleasing, and has been interpreted appropriately. The conclusions reached are important and completely new; the authors have discovered a novel signalling pathway that links Roundabout-2 (Robo2) receptor signalling to Cdc42 inactivation which, in turn, increases synaptic OXT content.

My only concerns relate to the narrative of the manuscript, which need some attention to improve the presentation of this otherwise excellent story.

The Introduction should be rewritten to provide a more cogent rational for the subsequent studies. The first sentence of the first paragraph should be followed by paragraph 3. This should be followed by an enunciation of a hypothesis that incorporates a possible role for the axonal cytoskeleton and Robo signalling in synaptic OXT content.

The work raises some interesting and important questions. This is a comprehensive and self-contained piece of work, and I am not suggesting that these issues need to be experimentally addressed. That said, the Discussion should be modified to take these points into consideration.

Firstly, the authors should speculate about the identity and source of the cognate ligand for the Robo2 receptor. Is there any evidence that secreted or membrane-bound Slit-family proteins are involved?

Secondly, the authors should integrate their findings into a more general discussion of excitation-synthesis-secretion coupling in OXT producing cells.

The Discussion ends rather abruptly. There should be a final paragraph that summarises the main findings.

*Reviewer \#3:*

This manuscript presents experiments in zebrafish to test the relationships between of actin, the Robo pathway and the oxytocin (OXT) content of neurohypophyseal axons. The experiments show that manipulations of actin, Robo deficiency and Cdc42 dominant active alter these axons and have mild effects on their OXT content.

Major issues:

1\) This study does not use the best possible approaches to support the main conclusions. The initial screen for changes in OXT content in axons uses light microscopy (dSTORM), which is good to first identify possible changes in OXT content, but this is not followed up by in depth analyses of individual synapses by electron microscopy (EM). Therefore, the main message remains vague and some aspects are not supported by strong enough data: The claim (in the title) that OXT accumulates \'in synapses\' needs EM. Throughout the manuscript, the authors use an axonal filler to define \"synapses\". Hence, altered OXT levels can be anywhere in the axons (e.g. vesicles being transported through the axon). And changes in axon organization may explain the main findings (see below). Claims about vesicles \"at the site of release\" (Abstract) are not supported by data.

The conclusion that \"the OXT content\" is altered is vague. Are there fewer vesicles per terminal, fewer terminal axon branches or filopodia, fewer varicosities per axon length, smaller vesicles, less OXT per vesicle etc.? The term \'actin state\' (Title) is also vague. What does that mean? Are release sites or varicosities larger?

One of the authors is from the \"Electron Microscopy Unit\" of the institute. Why is there no good EM to substantiate and better define the main conclusions?

2\) The effects of Robo deficiency are very mild: a 10% on LifeAct dynamic fraction and similar (opposite) effect on stable fraction. Changes in OXT \"accumulation\" are also small. These effects may be indirect and non-specific. Might they even be due to different genetic backgrounds between control and Robo-/- or Cdc42 fish? Certainly, claims like \"Robo2 is required....\" are misplaced.

3\) The effects of Cyto-D and Robo deficiency might be indirect and non-specific. In Figure 2 it is clear that changes in OXT content follow changes in total GFP signal (axonal filler). The effects of Cyto-D and Robo deficiency might primarily affect axonal organization (fewer terminal branches, filopodia, different axon diameter, different microtubule organization etc.). The mechanism of OXT accumulation in synapses may not be affected by Cyto-D, Robo deficiency or Cdc42.

10.7554/eLife.45650.030

Author response

\[Editors' note: the author responses to the first round of peer review follow.\]

Thank you and the reviewers for your constructive feedback on our manuscript entitled, \"Robo2 regulates synaptic oxytocin content by affecting actin state\". We have carefully read and discussed all of the reviewers\' comments, and in particular the issues which need to be addressed before publication. In your decision letter you wrote that the reviewers feel that addressing the most important issues will exceed what can be done in the two months' time period allowed for revision. However, since the initial submission of the manuscript in January, we have gathered and analysed new data which directly address the concerns raised by the reviewers and therefore we trust that we can provide a revised manuscript within the allotted time.

> Reviewer \#1:
>
> \[...\]
>
> 1\) Throughout the manuscript, most reference literature concerning the presynaptic functions of actin is rather old; definitely, authors have to i) include more recent literature, which reported important novel insights into actin\'s presynaptic functions, and ii) revise their manuscript (Introduction, Discussion) according to the findings reported in these studies.

We have revised the Introduction (paragraph two) and Discussion (paragraph two) to include recent works on actin's presynaptic functions.

> 2\) To prove that BoTxLCB indeed affect oxytocinergic synapses, the hypertonic osmotic challenge paradigm should be performed in the presence of BoTxLCB.

We have performed the requested experiment and now show that the increased synaptic OXT level we observed in BoTxLCB transgenic larvae under naïve conditions, is maintained following hypertonic challenge (new Figure 2J). This result is consistent with inhibition of OXT synaptic release by BoTxLCB.

> 3\) The authors exploited Lifeact in the assumption to specifically probe all F-actin, thereby neglecting several drawbacks of this tool. First, Lifeact is known for its high affinity for monomeric actin. Second, Lifeact\'s binding to F-actin is dependent on the presence of specific actin regulators (e.g. cofilin). Third, high Lifeact levels can affect endogenous F-actin structures. Authors have to include additional approaches to faithfully study the spatial distribution of F-actin in oxytocinergic synapses.

We agree with the reviewer that Lifeact has several drawbacks to probe F-actin. We have toned down our statement regarding the use of Lifeact to visualize spatial distribution of F-actin in oxytocinergic synapses (subsection "Disruption of F-actin affects synaptic OXT neuropeptide content" and Discussion paragraph five). As the reviewer suggested we now include an additional approach to detect F-actin in oxytocinergic synapses by using the Calponin domain of Utrophin fused to mCherry (UAS:mCherry-Utrophin-CH), which is a more-specific F-actin probe. We expressed mCherry-Utrophin-CH in OXT neurons in combination with our Tg(*oxt*:oxt-SP-EGFP) that labels OXT vesicles in synapses and found that mCherry-Utrophin-CH co-localizes with OXT-loaded synaptic vesicles (new Figure 6F). This result further supports our original suggestion that F-actin is enriched near OXT synaptic vesicles.

> 4\) It is not entirely clear to me, which of the data provided led authors to suggest that actin-coated vesicles were associated with the plasma membrane of oxytocinergic synapses? Authors have to include membrane-tagged reporters or a fluorescent volume marker in their experiments.

The reviewer is correct. We have removed this statement.

> 5\) Based on the aforementioned drawbacks of Lifeact, this probe is not suitable for studying F-actin turnover by FRAP. Authors should instead use GFP-actin, which has been proven to be highly useful to image actin functions in living cells and organisms.

As the reviewer suggested, we expressed GFP-actin specifically in OXT neurons, however this led to hypophyseal axon guidance defects in our in vivoexperimental system and precluded further analysis; these morphological abnormalities were not observed following OXT-specific expression of Lifeact-GFP. We also attempted to utilize the mCherry-Utrophin-CH probe, however, we were unable to perform FRAP experiments with this reagent due to the deep location, long wave length and high laser power required to perform mCherry FRAP with two-photon.

We agree with the reviewer about the drawbacks of Lifeact to study F-actin turnover by FRAP. We discuss Lifeact shortcomings in the revised manuscript (subsection "Disruption of F-actin affects synaptic OXT neuropeptide content" and Discussion paragraph five). Having said that, we still maintain that this experiment is informative in order to show that synaptic actin dynamics is altered in *robo2* mutants. Furthermore, we have now provided new information to demonstrate the causal effects of changes in actin dynamics on synaptic OXT content (see our reply to comment number 6 of this reviewer).

> 6\) Instead of using a global approach to link actin to the function of oxytocinergic synapses (treatment of larvae with cytochalasin D), authors should consider a genetic approach allowing manipulation of the actin cytoskeleton specifically in oxytocinergic neurons. Cytochalasin D effects on oxytocinergic synapses reported in this study may be rather indirect.

As suggested by this reviewer, to specifically test the role of actin in oxytocinergic synapses, we undertook a genetic approach by over-expressing Cofilin-EGFP specifically in oxytocin neurons using our transgenic tools (*oxt*:Gal4; UAS:Cofilin-EGFP). Cofilin is a member of ADF family of actin-binding proteins that promote F-actin depolymerization. We observed that expression of EGFP did not affect number and size of OXT puncta (new Figure 3J-K), however, expression of Cofilin-EGFP led to decreased OXT content as measured by puncta volume (new Figure 3N). These results suggest that actin have a direct role in regulating synaptic OXT content.

> 7\) The effects of Robo2 inactivation on Lifeact turnover and oxytocin vesicle mobility a rather low. Although authors found various parameters to be significantly different between controls and Robo2-deficient animals, it is unclear whether Robo2-dependent mechanisms are indeed relevant for oxytocin function and biology. Authors should include additional analyses to tackle this.

In response to this comment and a similar remark made by reviewer \#3, we calculated effect sizes (Cohen\'s D; Cohen, 2013) for the differences in stable vs. dynamic Lifeact fractions, and now show that the differences are in fact, quite large. Thus, when analyzing Lifeact stable vs. dynamic fractions in *robo2*+/+ compared to *robo2*-/-, Cohen\'s D is equal to 0.67 (subsection "Robo2 regulates synaptic actin dynamics").

We would like to emphasize that the significant oxytocin vesicle mobility defect (Genotype x Time is p\<0.0001) in *robo2* -/- mutant is for a period of 5 minutes of live imaging the synapses. The cumulative effect of this over a longer period can lead to a larger effect. This is exemplified in reduced OXT content in *robo2*-/- for which we also calculated Cohen's D of 0.82 indicating large effect size (new Figure 5D) (subsection "Slit3-Robo2 signalling regulates synaptic OXT content").

Finally, we respect the reviewer comment regarding analysis of oxytocin function and biology in *robo2* mutants, however we feel that measuring oxytocin-relevant physiological and behavioural outcomes are beyond the scope of this manuscript.

> Reviewer \#2:
>
> \[...\]
>
> My only concerns relate to the narrative of the manuscript, which need some attention to improve the presentation of this otherwise excellent story.
>
> The Introduction should be rewritten to provide a more cogent rational for the subsequent studies. The first sentence of the first paragraph should be followed by paragraph 3. This should be followed by an enunciation of a hypothesis that incorporates a possible role for the axonal cytoskeleton and Robo signalling in synaptic OXT content.

We have now extensively revised the Introduction and also incorporated the suggestions by the reviewer.

> The work raises some interesting and important questions. This is a comprehensive and self-contained piece of work, and I am not suggesting that these issues need to be experimentally addressed. That said, the Discussion should be modified to take these points into consideration.
>
> Firstly, the authors should speculate about the identity and source of the cognate ligand for the Robo2 receptor. Is there any evidence that secreted or membrane-bound Slit-family proteins are involved?

The role of cognate ligand for the Robo2 receptor is now demonstrated in the new Figure 5F-R. In short, we recently identified that cognate ligand of Robo2, *slit3* is highly expressed in the hypophyseal tissue (Anbalagan et al., 2018). We have performed additional genetic gain/loss-of-function experiments to study the role of Slit3 in regulating synaptic OXT content. Knockdown of *slit3* led to reduced OXT content similar to the *robo2* mutant phenotype (new Figure 5I). Conversely, ectopic expression of Slit3 in the neighbouring POMC-positive cells led to increased OXT content, but only in those neurohypophyseal synapses, which were in very close proximity to Slit3-overexpressing cells (new Figure 5L-R).

These results suggest that Slit3-Robo2 signalling regulate synaptic OXT levels.

> Secondly, the authors should integrate their findings into a more general discussion of excitation-synthesis-secretion coupling in OXT producing cells.

We have added a discussion paragraph regarding the possible role of Slit3-Robo2 signalling and excitation-secretion coupling (Discussion paragraph seven).

> The Discussion ends rather abruptly. There should be a final paragraph that summarises the main findings.

We added a concluding sentence to the Discussion.

> Reviewer \#3:
>
> \[...\]
>
> Major issues:
>
> 1\) This study does not use the best possible approaches to support the main conclusions. The initial screen for changes in OXT content in axons uses light microscopy (dSTORM), which is good to first identify possible changes in OXT content, but this is not followed up by in depth analyses of individual synapses by electron microscopy (EM). Therefore, the main message remains vague and some aspects are not supported by strong enough data: The claim (in the title) that OXT accumulates \'in synapses\' needs EM. Throughout the manuscript, the authors use an axonal filler to define \"synapses\".

It is well accepted that the axonal varicosities/swellings of hypothalamic magnocellular OXT neurons, which converge into the neurohypophysis are bona fidesynaptic release sites that store OXT-containing LDCV and release them upon physiological demand (Miyata et al., 2001; Wittkowski and Brinkmann, 1974). We agree with this reviewer that this has not been demonstrated in zebrafish larvae. To address the reviewer concerns (detailed below) we now provide new data from independent experimental approaches:

a\) "The claim (in the title) that OXT accumulates \'in synapses\' needs EM." As the reviewer requested we teamed up with Dr. Eyal Shimoni from our institute's electron microscopy (EM) unit and performed transmitted electron microscopy (TEM) in which we used our transgenic *oxt*:EGFP reporter as a fluorescent landmark to localize neurohypophyseal axonal swellings. We now show that electron-dense large dense core vesicles containing neuropeptides are indeed enriched in larval zebrafish neurohypophyseal synapses (Figure 1A-C). These synapses also have classical neurosecretory characteristics described in other species, including membrane fusion event during the exocytosis of LDCVs content (Figure 1B') into the perivascular space, as well as vesicle recycling events (Figure 1C'). Such exocytotic activity have been previously reported in neurohypophyseal synapses (Boudier, 1974; Buma and Nieuwenhuys, 1987; Crosnier et al., 2010; Damer and Creutz, 1994; De Camilli, 1995; Douglas, 1970; Douglas, 1973; Hayashi et al., 1994).

b\) "The authors use an axonal filler to define "synapses"." We provide additional evidence for the synaptic identity of OXT-positive neurohypophyseal axonal swellings using the transgenic synaptic vesicle reporter, Synaptophysin-EGFP. We now show that practically all analysed oxytocin-positive puncta co-localize with Synaptophysin (mean weighted correlation coefficient = 0.87; n=5 larvae new Figure 1D,E).

Notably, larval zebrafish neurohypophysis is very small (\~20x50μm) and is hard to localize for EM analysis, hence it is not practical to quantify neuropeptide content using EM. Having demonstrated the synaptic identity of OXT-positive swellings we took advantage of the transparent zebrafish larvae combined with precise genetic tools and reporters to quantify OXT synapses using confocal images on immunostained fixed samples and multi-photon based imaging on live transgenic larvae.

> Hence, altered OXT levels can be anywhere in the axons (e.g. vesicles being transported through the axon). And changes in axon organization may explain the main findings (see below). Claims about vesicles \"at the site of release\" (Abstract) are not supported by data.

We agree that changes in axon organization may explain the main findings. To address this point, we quantified the number and size of the neurohypophyseal synapses as well as the numbers of projecting axons. We observe no differences in those parameters following genetic perturbation of *slit3* and *robo2* as well as following OXT-specific gain-of-function of the actin regulator cofilin (new Figure 3 and 5).

In view of the new data presented above we maintain that we are analysing OXT levels and synaptic vesicles dynamics at the site of release.

> The conclusion that \"the OXT content\" is altered is vague. Are there fewer vesicles per terminal, fewer terminal axon branches or filopodia, fewer varicosities per axon length, smaller vesicles, less OXT per vesicle etc.?

As shown in our EM image (Figure 1B,C), neurohypophyseal synapses contain multiple large dense core vesicles (LDCVs).

Analysis of OXT content is based on immune-reactive OXT puncta that colocalized with genetically EGFP-tagged synapses. Due to the elaborate 3D structure of neurohypophyseal projections we are unable to reliably quantify axon branches or filopodia/varicosities per axon. Our real-time analysis of synaptic OXT vesicles accumulation suggests that the decreased volume of OXT puncta in neurohypophyseal synapses, following various perturbations of actin dynamics is most likely due to reduced OXT content in the synapses (i.e. fewer OXT containing LDCVs).

> The term \'actin state\' (Title) is also vague. What does that mean? Are release sites or varicosities larger?

We have modified the term 'actin state' to 'actin dynamics'.

We did not observe changes in varicosities sizes following *robo2-/-, slit3* knockdown (new Figure 5A-J) as well as following OXT-specific gain-of-function of cofilin (new Figure 3-N). Thus, we surmise that the outcome of these actin perturbations is not reflected in parameters relating to the shape of the cell (changes in varicosity size, branch points, axon guidance, etc.), but rather to changes in the dynamics of the actin cytoskeleton which affects OXT-vesicle mobility/accumulation in neurohypophyseal synapses.

> One of the authors is from the \"Electron Microscopy Unit\" of the institute. Why is there no good EM to substantiate and better define the main conclusions?

As mentioned above, we teamed up with an EM expert, Dr. Eyal Shimoni, and now provide new ultrastructure images to substantiate our claims. Dr. Shimoni was added as a co-author to the revised manuscript.

> 2\) The effects of Robo deficiency are very mild: a 10% on LifeAct dynamic fraction and similar (opposite) effect on stable fraction. Changes in OXT \"accumulation\" are also small. These effects may be indirect and non-specific. Might they even be due to different genetic backgrounds between control and Robo-/- or Cdc42 fish? Certainly, claims like \"Robo2 is required....\" are misplaced.

Control for all experiments involving the effects of Robo2 were performed using larvae derived from in-cross of *robo2*+/- fish (i.e. full siblings), ruling out that changes in Lifeact dynamic and OXT accumulation are due to differences in genetic background.

Furthermore, as mentioned in our response to comment \#7 of reviewer \#1, we now provide effect sizes (Cohen\'s D) for all relevant analyses and show that the effect sizes of actin perturbations on synaptic OXT content are in fact, quite large. Thus, in the case of the Lifeact stable vs. dynamic fractions (new Figure 4E,F), Cohen\'s D is equal to 0.67, and in the case of accumulation of OXT content in synapses (new Figure 5D) Cohen's D is 0.82. For a discussion of statistical analyses of FRAP experiments, please see our reply to the specific comment by this reviewer regarding statistical treatment of these types of experiments (final comment).

Lastly, we agree with the reviewer that other Robo2-independent actin-regulatory mechanisms can regulate synaptic actin dynamics. We have therefore changed the wordings "Robo2 is required..." to "Robo2 regulates..." throughout the manuscript.

> 3\) The effects of Cyto-D and Robo deficiency might be indirect and non-specific: In Figure 2 it is clear that changes in OXT content follow changes in total GFP signal (axonal filler). The effects of Cyto-D and Robo deficiency might primarily affect axonal organization (fewer terminal branches, filopodia, different axon diameter, different microtubule organization etc.). The mechanism of OXT accumulation in synapses may not be affected by Cyto-D, Robo deficiency or Cdc42.

We agree with the reviewer that the effect of Cyto-D can be also due to changes in the size of neurohypophyseal synapses. As mentioned in our reply to reviewer \#1 (comment \#6), we now provide additional experiments to directly test the role of F-actin and CDC42 in regulating synaptic OXT content. Thus, we undertook an alternative genetic approach to conditionally express either the Actin depolymerizing factor Cofilin or constitutively-active (i.e. GTP-bound) mutant form of CDC42, specifically in OXT neurons. Both of these cell type specific perturbations of Actin dynamics led to decreased OXT content (new Figure 3I-N and new Figure 7---figure supplement 1).

[^1]: These authors contributed equally to this work.
